Navigation Links
Genetic tug of war determines sexual differentiation

Whether or not a fertilized mammalian egg ultimately develops into a male or female is determined by the winner of a tug of war between two different genes encoding signaling proteins and the divergent pathways they control, according to a new study led by Duke University Medical Center cell biologists.

In their experiments in mice, the researchers found that two specific genes, Wnt4 and Fgf9, are in equal balance in the early stages of development in the mammalian gonad before it commits to either a male testis or a female ovary. If this equilibrium is tipped in favor of Wnt4, the gonad develops into an ovary, while an Fgf9 victory leads to the formation of a testis.

What tips the balance in favor of male is a third gene, Sry, located on the Y chromosome in the genome and known to be the primary sex-determining gene in mammals. When this gene becomes activated at a crucial moment in the early gonad's development, it favors Fgf9 and leads to the development of a testis.

"We found that Sry accomplishes this feat by triggering still another gene, the Sox9 gene. Sox9 activates the Fgf9 gene which blocks Wnt4 and initiates a cascade of events leading to the development of a testis," said Blanche Capel, Ph.D., senior member of the international research team. "If XY mice lose Fgf9, they develop ovaries, while XX mice that lose Wnt4 develop incomplete testes. This suggests that vertebrate sex determination results from the interplay between these two opposing signals."

The researchers published their findings in the May 22, 2006, issue of the journal Public Library of Science-Biology. Their research was supported by the National Institutes of Health.

In mammals, a fertilized egg with two X chromosomes will become a female, while an egg with an X and Y chromosome will become a male. However, during embryonic development, the gonad has the ability to transform either into a testis or an ovary. During the earliest stages of development
'"/>

Source:Duke University Medical Center


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Genetically modified natural killer immune cells attack, kill leukemia cells
3. Ants Genetic Engineering Leads To Species Interdependency
4. Genetic Variation Visualization - From EMBL
5. Genetically modified rice in China benefits farmers health, study finds
6. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
7. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
8. Genetic defects give the immune system the green light to attack the pancreas
9. Maine Researchers Find Exceptions to Old Rules of Genetic Inheritance
10. Genetic therapy reverses nervous system damage in animal model of inherited human disease
11. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
Post Your Comments:
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4